Annual report pursuant to Section 13 and 15(d)

Schedule of Accrued Expenses (Details)

v3.21.1
Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Payables and Accruals [Abstract]    
Payroll and incentives $ 1,094 $ 978
General and administrative expenses 280 441
Research and development expenses 778 421
Deferred revenue and other deferred liabilities * [1] 643 100
Total $ 2,795 $ 1,940
[1] At December 31, 2020, approximately $576.6 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately $66.6 thousand is deferred revenue related to the Genentech feasibility study agreement. The $100.0 thousand of deferred revenue at December 31, 2019 is the upfront payment for the Genentech feasibility study agreement.